Day: March 20, 2024

A total of 9,394 hotels or 912,444 hotel rooms in operation as of December 31, 2023. Hotel turnover1 increased 55.0% year-over-year to RMB20.4 billion in the fourth quarter of 2023. Excluding Steigenberger Hotels GmbH and its subsidiaries (“DH”, or “Legacy-DH”), hotel turnover increased 60.6% year-over-year in the fourth quarter of 2023 and increased 65.9% year-over-year for the full year of 2023. Revenue increased 50.7% year-over-year to RMB5.6 billion (US$786 million)2 in the fourth quarter of 2023, surpassing the revenue guidance previously announced of a 41% to 45% increase compared to the fourth quarter of 2022, and increased 57.9% year-over-year to RMB21.9 billion (US$3.1 billion) for the full year of 2023. Revenue from the Legacy-Huazhu segment in the fourth quarter of 2023 was RMB4.4 billion, which increased 59.0% year-over-year,...

~ Q4 Net Sales increased 18.0%; Q4 Comparable Store Sales increased 3.9% ~ ~ Q4 Earnings per Share increased 44.7% to $1.23 ~ ~ Q4 Adjusted Earnings per Share increased 46.4% to $1.23 ~ ~ Raising long-term store target to 1,300 from 1,050 ~ HARRISBURG, Pa., March 20, 2024 (GLOBE NEWSWIRE) — Ollie’s Bargain Outlet Holdings, Inc. (NASDAQ: OLLI) (the “Company”) today reported financial results for the fourth quarter and full-year fiscal 2023. Fourth Quarter Summary:Total net sales increased 18.0% to $648.9 million. Excluding the impact of the 53rd week, net sales increased 11.9%. Net sales in the 53rd week were $34.0 million and contributed approximately $0.04 to diluted earnings per share. Comparable store sales increased 3.9% from the prior year increase of 3.0%. The Company opened 7 new stores, ending the quarter with 512 stores...

Presented positive 72-week data from the Phase 2b ORIGIN clinical trial, setting a new standard in IgAN with no loss of kidney function over the duration of treatment Actively adding sites and enrolling pivotal Phase 3 ORIGIN 3 study of atacicept for the treatment of IgAN; topline data expected in 1H 2025 Completed $287.5 million financing, further strengthening the Company’s balance sheet and extending the Company’s expected cash runway through potential approval and commercial launchBRISBANE, Calif., March 20, 2024 (GLOBE NEWSWIRE) — Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunologic diseases, today reported its business highlights and financial results for the fourth quarter and year ended...

Delivered record results, growing revenue 20% and Adjusted EBITDA 33% for fiscal 2023Targeting strong outlook in 2024 of at least 20% growth in revenue and Adjusted EBITDAAuthorizes $200 million Share Repurchase Program ST. GALLEN, Switzerland, March 20, 2024 (GLOBE NEWSWIRE) — Sportradar Group AG (NASDAQ: SRAD) (“Sportradar” or the “Company”), a leading global sports technology Company focused on creating immersive experiences for sports fans and bettors, today announced financial results for its fourth quarter and year ended December 31, 2023. Carsten Koerl, Chief Executive Officer of Sportradar, said: “2023 was another dynamic and successful year for the Company delivering our 3rd consecutive year of more than 20% revenue growth, improved profitability, and margin expansion. We are pleased with our growth momentum, fueled by...

EDEN PRAIRIE, MN, March 20, 2024 (GLOBE NEWSWIRE) — via NewMediaWire – SANUWAVE Health, Inc. (the “Company” or “Sanuwave”) (OTCQB: SNWV), a leading provider of next-generation FDA-approved wound care products, will host a live conference call on Friday, March 22, 2024, at 8:30 AM (ET) to present the Q4 and FY2023 financial results Telephone access to the call will be available by dialing the following numbers: Participant Listening: 1-800-267-6316 or 1-203-518-9783 OR click the link for instant telephone access to the event. https://viavid.webcasts.com/starthere.jsp?ei=1661785&tp_key=8f8d9c1839 Materials for the conference call will be included on the company website at www.sanuwave.com/investors. A replay will be made available through April 15, 2024: Toll-Free: 1-844-512-2921 or 1-412-317-6671 Replay Access...

LAVA-1207 progressing in Phase 1/2a study, with pembrolizumab combination expected to begin in Q2 2024 In March 2024, Pfizer paid LAVA $7 million for achieving a clinical milestone for EGFRd2 (PF-08046052/formerly LAVA-1223)LAVA 1266 tracking to Q2 2024 IND submission Strong balance sheet with cash of $95.6 million supports runway into 2026UTRECHT, The Netherlands and PHILADELPHIA, March 20, 2024 (GLOBE NEWSWIRE) — LAVA Therapeutics N.V. (NASDAQ: LVTX, “LAVA,” “the Company”), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody® platform of bispecific gamma-delta (δ2) T cell engagers, today announced recent corporate highlights and financial results for the fourth quarter and year ended December 31, 2023. “In 2023, we advanced our portfolio of proprietary Gammabody® programs. LAVA-1207...

DUBLIN and SHANGHAI, March 20, 2024 (GLOBE NEWSWIRE) — PDD Holdings Inc. (“PDD Holdings” or the “Company”) (NASDAQ: PDD), today announced its unaudited financial results for the fourth quarter ended and the fiscal year ended December 31, 2023. Fourth Quarter 2023 HighlightsTotal revenues in the quarter were RMB88,881.0 million (US$1 12,518.6 million), an increase of 123% from RMB39,820.0 million in the same quarter of 2022.Operating profit in the quarter was RMB22,395.0 million (US$3,154.3 million), an increase of 146% from RMB9,113.7 million in the same quarter of 2022. Non-GAAP2 operating profit in the quarter was RMB24,579.9 million (US$3,462.0 million), an increase of 112% from RMB11,600.1 million in the same quarter of 2022.Net income attributable to ordinary shareholders in the quarter was RMB23,280.3 million (US$3,279.0...